Regular Article
Accumulation of mtDNA with a Mutation at Position 3271 in tRNALeu(UUR) Gene Introduced from a Melas Patient to HeLa Cells Lacking mtDNA Results in Progressive Inhibition of Mitochondrial Respiratory Function

https://doi.org/10.1006/bbrc.1993.2584Get rights and content

Abstract

A new mitochondrial DNA (mtDNA) mutation of tRNALeu(UUR) at nucleotide position 3271 (MELAS3271) was determined to be involved in the pathogenic process of mitochondrial diseases MELAS (mitochondnal myopathy, encephalopathy, lactic acidosis and stroke-like episodes) using intercellular transfer of patient-derived mtDNA to mtDNA-less HeLa cells (ρ0 HeLa cells). Cybrid clones containing imported mtDNA exclusively from a MELAS patient with MELAS3271 mtDNA were isolated, and the influence of MELAS3271 mtDNA on mitochondrial translation activity and mitochondrial respiratory complex I enzyme activity were examined. Accumulation of more than 87% MELAS3271 mutant mtDNA in the cybrid clones induced both low complex I activity and abnormal mtDNA-encoded polypeptide synthesis including at least complex I subunit ND6. suggesting involvement of the new MELAS-associated mutation in the pathogenesis.

References (0)

Cited by (69)

  • Identification of FASTKD2 compound heterozygous mutations as the underlying cause of autosomal recessive MELAS-like syndrome

    2017, Mitochondrion
    Citation Excerpt :

    Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS, MIM 540000) are a genetically heterogeneous disorder with varying clinical phenotypes. The main underlying causes of the MELAS have been reported as mutations in MTTL1 including m.3243A > G (Goto et al., 1990; Goto, 1995; Hayashi et al., 1993; Sato et al., 1994). In addition, mutations in the MTND1, MTND5, MTND6, MTTQ, MTTH, MTTK, MTTC, MTTS1, and MTTS2 have also been reported to cause MELAS (Corona et al., 2001; Kirby et al., 2004; Santorelli et al., 1997).

  • Generation of Transmitochondrial Mice: Development of Xenomitochondrial Mice to Model Neurodegenerative Diseases

    2007, Methods in Cell Biology
    Citation Excerpt :

    To circumvent problems associated with variability and instability of mitochondrial populations in heteroplasmic cells, microinjection can be carried out in ρ0 cells, which contain no mtDNA and require uridine and pyruvate in culture media for their survival (King and Attardi, 1989). Previous studies revealed that human cybrid cell lines containing mutant mtDNA for a number of mtDNA‐related diseases could be produced by introduction of isolated patient mitochondria into ρ0 cells (Chomyn et al., 1991; Hayashi et al., 1991, 1993; Trounce et al., 1994, and in many reports since). To develop transmitochondrial mice, we would take advantage of breakthroughs in embryonic stem (ES) cell‐based technologies and the work of Levy et al. (1999), where ES cells were used to transfer a foreign mitochondrial genome into mouse blastocysts and immortalized human and mouse ρ0 cell lines (Bai and Attardi, 1998; King and Attardi, 1989; Trounce et al., 2000).

View all citing articles on Scopus
View full text